Use of Remote Monitoring for COVID-19 Patient
- Conditions
- COVID
- Interventions
- Device: LifeSignals Biosensor 1AX*Other: Standard of Care
- Registration Number
- NCT04425720
- Lead Sponsor
- Montefiore Medical Center
- Brief Summary
The central hypothesis motivating this study is that remote patient monitoring (RPM) of infectious disease patients can efficiently facilitate self-isolation. Additionally, RPM can assist in more rapid identification of patients at risk, facilitate detection of patient deterioration, and enable early interventions, all of which play a vital role in resource utilization and outcomes.
- Detailed Description
Aim-I To develop and test a clinical care pathway that can be utilized in similar epidemic conditions in the future. To study this aim, the investigators will be using the COVID-19 medical surge as a condition to evaluate the framework of delivering care through remote patient monitoring. The success of this care delivery model will be evaluated on ease of model implementation, patient satisfaction, clinical outcomes, and the utilization of shared decision making.
Aim-II To evaluate remote patient monitoring for appropriate resource utilization in epidemic and pandemic conditions. To evaluate this aim, the investigators plan to compare the emergency department (ED) visits and in-patient admission of patients with and without wearable remote patient monitoring devices. Additionally, the investigators will compare the number of patients that required critical interventions (mechanical ventilation and ECMO) during the hospital stay.
Aim III To evaluate the utilization of wearable technology for upfront predictions of patients that would require in-patient admissions. To evaluate this aim, patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary. The comparison group will be patients undergoing routine standard of care at the hospital. ED visits, in-patient hospital admissions, and patient satisfaction will be the outcome measures compared between the two groups.
Aim IV To evaluate the association between early identification of critical, abnormal vital signs and the prevention of serious adverse events. To evaluate this aim, patients in the monitored group and non-monitored group will be compared for ED visits, in-patient admissions, length of hospital stay, and serious adverse events.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- Covid-19 positive patient
- Does not require in-patient admission
- Allergic to sensor patch
- Has implanted pacemaker
- Has excessive sweating
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Monitored LifeSignals Biosensor 1AX* Patients who are diagnosed with COVID-19 and are undergoing self-quarantine will be closely monitored using a wearable device, and shared-clinical decisions will be made based on the monitored data and patient diary Standard Of Care Standard of Care Patients without wearable monitoring technology undergoing routine standard of care at the hospital.
- Primary Outcome Measures
Name Time Method Number of Monitored Versus Non-Monitored In-patient Admission 14 days compare the number of in-patient admissions between the monitored and non-monitored patients
How Many Subjects Needed to Visit the Emergency Department 14 days compare the number of participants who visited Emergency Department between both arms
Length of Stay 14 days Length of stay of subject if hospitalized
How Many Completed the Patient Satisfaction Survey 14 days Survey given to patients who were monitored to ask about satisfaction with the program. A research associate calls enrolled subjects to determine their opinions having participated in the program.
How Many Subjects End up Requiring Mechanical Ventilation and ECMO 14 days How often does a subject end up getting mechanical ventilation or ECMO
Serious Adverse Events 14 days events requiring extended hospital stay
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Montefiore Medical Center
🇺🇸Bronx, New York, United States